Rural-Urban Variation in Guideline-Concordant Management of Early-Stage Kidney, Prostate, and Testicular Cancer in the United States (2010–2022)

Rural U.S. patients with early-stage kidney and prostate cancer were up to 26% less likely to receive guideline-concordant care than urban patients

Journal: Urologic Oncology | Published: 2026-03-31 | Type: Retrospective cohort (SEER) | PMID: 41925394 Authors: Dirican et al. (NYMC/St. Mary's General Hospital, NJ; St. Michael's Medical Center, NJ) Funding/COI: No funding listed. Authors declare no competing interests.

Summary

Using SEER data on 516,105 patients diagnosed from 2010–2022, this study finds that rural residence is independently associated with lower rates of NCCN guideline-concordant care for early-stage kidney and prostate cancer, even after adjusting for demographics, clinical stage, and time period. For cT1a kidney cancer, partial nephrectomy — the nephron-sparing standard — was performed 57.8% of the time in urban counties vs. 49.9% in rural-remote counties. For prostate cancer, the gap held even among men ineligible for active surveillance, who by guidelines should receive definitive local therapy. Testicular cancer looked better on paper (>90% concordance), but rural patients were underrepresented in that arm, limiting conclusions.

Claims

• Kidney cancer (cT1a, n=72,681): Partial nephrectomy rate was 57.8% urban, 50.5% rural-adjacent, 49.9% rural-remote; after multivariable adjustment, rural-adjacent aOR 0.74 (95% CI 0.70–0.79) and rural-remote aOR 0.72 (95% CI 0.67–0.78) for receiving PN vs. radical nephrectomy or no surgery
• Prostate cancer (n=439,435): Overall guideline-concordant management: rural-adjacent aOR 0.82 (95% CI 0.80–0.84), rural-remote aOR 0.74 (95% CI 0.71–0.76)
• Prostate cancer (AS-ineligible men only): Definitive local therapy rates were 81.6% urban, 78.5% rural-adjacent, 76.8% rural-remote — men who had no business being on surveillance were still not getting treated at guideline rates
• Testicular cancer (n=3,989, stage I–II GCT): >90% guideline concordance across all rurality groups, but rural subgroups were small and the finding should be interpreted cautiously

Study Quality

SEER is the right database for this question — large, population-based, validated cancer registry covering ~28% of the U.S. population, with county-level FIPS codes linkable to USDA Rural-Urban Continuum Codes. The analytic approach is solid: multivariable logistic regression adjusting for age, race/ethnicity, year of diagnosis, insurance, and clinical factors, with prespecified subgroup analyses (AS-ineligible prostate cancer). Using NCCN pathways as the concordance benchmark is appropriate and operationally well-defined here — they spell out exactly what "concordant" means for each cancer type.

The core limitation is inherent to SEER: it captures initial treatment but not why a patient received (or didn't receive) a given treatment. Distance to a urologic surgeon? Patient preference? Referral failure? Insurance denial? The database can't distinguish these, and the paper doesn't try to. The adjusted odds ratios are credible, but the mechanistic story is inference, not measurement.

Red Flags

• No funding listed — unusual for a multi-institution registry study of this scale; warrants noting even if unlikely to bias the results
• Testicular cancer arm is underpowered for rural analysis — 3,989 total with limited rural representation; the >90% concordance finding should not be used to conclude rural-urban parity exists for this cancer
• SEER lacks granular socioeconomic data — income, education, and insurance type beyond broad categories cannot be adjusted for, and these likely mediate much of the rurality effect
• No outcomes data — the study measures whether guideline-concordant care was delivered, not whether it improved survival or kidney function; the clinical stakes of these disparities are implied, not quantified
• Single author affiliation cluster — all authors from a single NJ hospital system; no obvious conflict but limits perspective on geographic generalizability of their interpretations

Strengths

• Large, population-based sample (516K+ patients across 12 years)
• Prespecified subgroup analysis for AS-ineligible prostate cancer addresses a key confound (men receiving observation may be doing so appropriately)
• USDA continuum codes provide more geographic granularity than a simple urban/rural binary
• Consistent direction of effect across two distinct cancer types (kidney, prostate) strengthens the overall inference
• Long time window (2010–2022) allows assessment of whether gaps have narrowed over time — they haven't meaningfully

Verdict

This is a competent registry study doing what registry studies do well: documenting a disparity at scale. The finding — that rural patients are less likely to receive the kidney-sparing surgery their guidelines recommend and less likely to get definitive treatment for prostate cancer that warrants it — is not surprising, but the numbers are specific and the adjustment is credible. The paper's weakness is that it can't tell you why the gap exists, and the authors' call for "investments in rural surgical and radiation access" is policy advocacy, not a finding. Worth reading for the odds ratios; don't expect mechanistic insight.